KEN WINDLE B.Pharm.
Ken co-founded Advent in 2001. In his prior career with Glaxo/GlaxoWellcome (now GSK) spanning 35 years, he held senior commercial and regional leadership positions in UK, Asia and Australia and was Regional Director of Asia Pacific and Managing Director of Glaxo Australia. He was a member of Innovation Australia for 6 years.
Ken currently serves as a Board member of Aus Bio, Opal Biosciences and chairs the Pharmacy degree Program Advisory Committee at the Royal Melbourne Institute of Technology. Ken holds a Pharmacy degree from the University of Otago, New Zealand.
DR ANNE BRINDLEY B.Pharm. (Hons), Ph.D.
Chief Executive Officer / Director
Anne joined Advent in 2017 and has > 27 years experience in the pharma industry, primarily in inhalation product development. After starting her career in Glaxo (now GSK), Anne went on to hold leadership roles at AstraZeneca (Director of Product Development, encompassing all inhaled products), Skyepharma (Executive VP Pharmaceutical Development) and Johnson & Johnson (as Managing Director of Respivert). Anne has led the development of several products through to registration / market including Symbicort, Pulmicort and Flutiform and has progressed a wide range of other inhaled products (metered dose inhalers, dry powder inhalers and nebuliser products) through all stages of development.
Anne holds a Pharmacy degree from the University of Bath and a Ph.D. from the University of Nottingham (UK).
DR ALAN ROBERTSON B.Sc. Ph.D.
Alan has over 30 years' experience in the pharmaceutical industry. In his early career in Medicinal Chemistry for Wellcome, he invented the migraine drug, Zomig. Then at Faulding, he developed generic injectable cancer drugs before serving as Head of Drug Development at Amrad (that became part of CSL). As Head of Drug Discovery at Kinacia, he invented an antiplatelet drug that was licensed to Astra Zeneca. Alan was also CEO of Praxis and Promics. Praxis became Pharmaxis and, as CEO from start up in 1999 to 2013, Alan listed the company on the Australian Stock Exchange and NASDAQ, raising over $350 million in the US, Europe and Australia. Under his leadership, Pharmaxis achieved international approvals of an inhaled treatment for cystic fibrosis and built a successful drug discovery capability. As CEO of Promics (now part of Teva), he developed the first C5a receptor antagonist for rheumatoid arthritis.
Alan is currently CEO of Alsonex, Chairman of AllVascular and an advisor to Iggy Get Out and the Children’s Cancer Institute of Australia. Alan holds a B.Sc. and a Ph.D. in synthetic organic chemistry from the University of Glasgow and undertook a three-year post-doctoral appointment with Nobel Laureate, Professor Sir John Cornforth, at the University of Sussex, UK.